Press Releases
February 03, 2015
Gilead Sciences Announces Fourth Quarter and Full Year 2014 Financial Results
- Fourth Quarter Product Sales of
- Full Year 2014 Product Sales of
- Full Year 2014 Non-GAAP EPS of
Full year 2014 total revenues were
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| December 31, | December 31, | ||||||||||||||
| (In millions, except per share amounts) | 2014 | 2013 | 2014 | 2013 | |||||||||||
| Product sales | $ | 7,222 | $ | 3,043 | $ | 24,474 | $ | 10,804 | |||||||
| Royalty, contract and other revenues | 92 | 77 | 416 | 398 | |||||||||||
| Total revenues | $ | 7,314 | $ | 3,120 | $ | 24,890 | $ | 11,202 | |||||||
| Net income attributable to Gilead | $ | 3,487 | $ | 791 | $ | 12,101 | $ | 3,075 | |||||||
| Non-GAAP net income attributable to Gilead | $ | 3,883 | $ | 930 | $ | 13,314 | $ | 3,451 | |||||||
| Diluted EPS | $ | 2.18 | $ | 0.47 | $ | 7.35 | $ | 1.81 | |||||||
| Non-GAAP diluted EPS | $ | 2.43 | $ | 0.55 | $ | 8.09 | $ | 2.04 | |||||||
Product Sales
Total product sales for the fourth quarter of 2014 were
Antiviral Product Sales
Antiviral product sales were
Other Product Sales
Other product sales, which include Letairis®, Ranexa®
and AmBisome®, totaled
Operating Expenses
During the fourth quarter and full year 2014, compared to the same periods in 2013:
-
Non-GAAP research and development (R&D) expenses increased due to
continued progression of Gilead's product pipeline, in particular in
the oncology and liver disease areas, support of geographic expansion,
up-front fees paid in connection with Gilead's collaboration with
ONO Pharmaceutical Co., Ltd. (ONO) and the purchase of aU.S. Food and Drug Administration (FDA ) priority review voucher. -
Non-GAAP selling, general and administrative (SG&A) expenses increased
primarily due to Gilead's business growth, including commercial
expansion related to the launches of Sovaldi and Harvoni, and Gilead's
portion of the non-tax deductible branded prescription drug fee for
which accounting guidance was finalized in the third quarter resulting
in a one-time catch up of
$460 million in 2014.
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| December 31, | December 31, | ||||||||||||||
| (In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||
| Non-GAAP research and development expenses | $ | 899 | $ | 511 | $ | 2,585 | $ | 1,948 | |||||||
| Non-GAAP selling, general and administrative expenses | $ | 799 | $ | 471 | $ | 2,757 | $ | 1,557 | |||||||
Note: Non-GAAP R&D and SG&A expenses exclude amounts related to acquisition, restructuring, stock-based compensation and other.
Cash,
As of
Full Year 2015 Guidance
Gilead provided its full year 2015 guidance:
| (In millions, except percentages and per share amounts) |
Provided
February 3, 2015 |
||
| Net Product Sales | $26,000 - $27,000 | ||
| Non-GAAP* | |||
| Product Gross Margin | 87% - 90% | ||
| R&D | $3,000 - $3,300 | ||
| SG&A | $3,000 - $3,300 | ||
| Effective Tax Rate | 18.0% - 20.0% | ||
| Diluted EPS Impact Related to Acquisition, Restructuring, Stock-Based Compensation and Other | $0.82 - $0.87 | ||
|
* Non-GAAP product gross margin, R&D and SG&A expenses and effective tax rate exclude amounts related to acquisition, restructuring, stock-based compensation and other. |
|||
Corporate Highlights
-
Announced that
Philippe C. Bishop , MD, joined the company as Senior Vice President, Hematology and Oncology Therapeutics and a member of Gilead’s executive committee. Dr. Bishop reports toJohn McHutchison , MD, Executive Vice President, Clinical Research and has responsibility for Gilead’s programs in oncology.
Product & Pipeline Updates Announced by
Antiviral Program
-
Announcement of expansion to Gilead’s agreement with
Janssen R&D Ireland Limited for the development and commercialization of a new once-daily single tablet regimen containing Gilead’s tenofovir alafenamide (TAF) and emtricitabine, and Janssen’s rilpivirine (RFTAF). The original agreement was established in 2009 for the development and commercialization of Complera, marketed as Eviplera in theEuropean Union , which combines tenofovir disoproxil fumarate, emtricitabine and rilpivirine in a once-daily tablet. -
Announcement of the
European Commission granting marketing authorization for Harvoni, the first once-daily single tablet regimen to treat chronic hepatitis C genotype 1 and 4 and subgroups of genotype 3 infected adults. -
Presentation of data on sofosbuvir-based regimens in chronic hepatitis
C virus (HCV) patients at the 65th Annual Meeting of the
American Association for the Study of Liver Diseases :- Positive results from several Phase 2 and Phase 3 studies evaluating investigational uses of Harvoni for the treatment of chronic HCV infection in patients with limited or no treatment options, including patients with decompensated cirrhosis, patients with HCV recurrence following a liver transplant and patients who failed previous treatment with other direct acting antivirals.
- Positive results from three Phase 2 open-label studies evaluating the safety and efficacy of an investigational all-oral pan-genotypic regimen containing sofosbuvir and the investigational NS5A inhibitor GS-5816 for the treatment of chronic HCV infection.
-
Submission of a New Drug Application (NDA) to the
FDA for an investigational, once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg (E/C/F/TAF) for the treatment of HIV-1 infection. The data submitted in the NDA support the use of the regimen among adult and adolescent treatment-naïve HIV individuals, virologically suppressed patients who switch regimens and those with renal impairment. If approved, E/C/F/TAF would be Gilead’s first single tablet regimen to contain TAF. -
Announcement of Harvoni approvals by
FDA andHealth Canada .
Oncology Program
- Announcement of an exclusive license agreement with ONO for the development and commercialization of ONO-4059, ONO’s oral Bruton’s tyrosine kinase inhibitor for the treatment of B-cell malignancies and other diseases.
-
Announcement of positive results from registrational studies further
describing the duration of response, progression-free survival and
safety profile for Zydelig® (idelalisib) in relapsed
patients with chronic lymphocytic leukemia and two types of indolent
non-Hodgkin lymphoma. The findings were presented at the Annual
Meeting of the
American Society of Hematology .
Conference Call
At
A replay of the webcast will be archived on the company's website for
one year, and a phone replay will be available approximately two hours
following the call through
About Gilead
Non-GAAP Financial Information
Gilead has presented certain financial information in accordance with U.S. GAAP (GAAP) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7 and 8.
Forward-looking Statements
Statements included in this press release that are not historical in
nature are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Gilead cautions readers that
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include: Gilead's ability to achieve its
anticipated full year 2015 financial results; Gilead's ability to
sustain growth in revenues for its antiviral, cardiovascular and
respiratory programs; availability of funding for state AIDS Drug
Assistance Programs (ADAPs); continued fluctuations in ADAP purchases
driven by federal and state grant cycles which may not mirror patient
demand and may cause fluctuations in Gilead's earnings; the possibility
of unfavorable results from clinical trials involving RFTAF, the single
tablet regimen of sofosbuvir with GS-5816 and idelalisib for new
indications; Gilead's ability to initiate clinical trials in its
currently anticipated timeframes; the levels of inventory held by
wholesalers and retailers which may cause fluctuations in Gilead's
earnings; Gilead's ability to submit NDAs for new product candidates in
the timelines currently anticipated; Gilead's ability to receive
regulatory approvals in a timely manner or at all, for new and current
products, including E/C/F/TAF; Gilead's ability to successfully
commercialize its products, including Sovaldi, Harvoni, Stribild and
Zydelig; the risk that physicians and patients may not see advantages of
Gilead's products over other therapies and may therefore be reluctant to
prescribe the products; the risk that estimates of patients with HCV or
anticipated patient demand may not be accurate; the risk that private
and public payers may demand significant discounts or rebates to include
Gilead's HCV products on formulary; the risk that we may experience
additional pricing pressure in light of the launch of a competitor's all
oral HCV regimen in
All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Gilead owns or has rights to various trademarks, copyrights and trade
names used in our business, including the following: GILEAD®,
ATRIPLA® is a registered trademark belonging to Bristol-Myers
Squibb &
For more information on
|
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) (in millions, except per share amounts) |
||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product sales | $ | 7,222 | $ | 3,043 | $ | 24,474 | $ | 10,804 | ||||||||
| Royalty, contract and other revenues | 92 | 77 | 416 | 398 | ||||||||||||
| Total revenues | 7,314 | 3,120 | 24,890 | 11,202 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of goods sold | 1,063 | 858 | 3,788 | 2,859 | ||||||||||||
| Research and development | 1,045 | 552 | 2,854 | 2,120 | ||||||||||||
| Selling, general and administrative | 876 | 513 | 2,983 | 1,699 | ||||||||||||
| Total costs and expenses | 2,984 | 1,923 | 9,625 | 6,678 | ||||||||||||
| Income from operations | 4,330 | 1,197 | 15,265 | 4,524 | ||||||||||||
| Interest expense | (130 | ) | (73 | ) | (412 | ) | (307 | ) | ||||||||
| Other income (expense), net | 30 | (11 | ) | 3 | (9 | ) | ||||||||||
| Income before provision for income taxes | 4,230 | 1,113 | 14,856 | 4,208 | ||||||||||||
| Provision for income taxes | 768 | 326 | 2,797 | 1,151 | ||||||||||||
| Net income | 3,462 | 787 | 12,059 | 3,057 | ||||||||||||
| Net loss attributable to noncontrolling interest | 25 | 4 | 42 | 18 | ||||||||||||
| Net income attributable to Gilead | $ | 3,487 | $ | 791 | $ | 12,101 | $ | 3,075 | ||||||||
| Net income per share attributable to Gilead common stockholders - basic | $ | 2.32 | $ | 0.52 | $ | 7.95 | $ | 2.01 | ||||||||
| Net income per share attributable to Gilead common stockholders - diluted | $ | 2.18 | $ | 0.47 | $ | 7.35 | $ | 1.81 | ||||||||
| Shares used in per share calculation - basic | 1,506 | 1,534 | 1,522 | 1,529 | ||||||||||||
| Shares used in per share calculation - diluted | 1,597 | 1,694 | 1,647 | 1,695 | ||||||||||||
|
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited) (in millions, except percentages and per share amounts) |
||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Cost of goods sold reconciliation: | ||||||||||||||||
| GAAP cost of goods sold | $ | 1,063 | $ | 858 | $ | 3,788 | $ | 2,859 | ||||||||
| Stock-based compensation expenses | (2 | ) | (1 | ) | (10 | ) | (7 | ) | ||||||||
| Acquisition related-amortization of purchased intangibles | (218 | ) | (80 | ) | (818 | ) | (143 | ) | ||||||||
| Variable interest entity consolidated costs (2) | 4 | — | 4 | — | ||||||||||||
| Non-GAAP cost of goods sold | $ | 847 | $ | 777 | $ | 2,964 | $ | 2,709 | ||||||||
| Product gross margin reconciliation: | ||||||||||||||||
| GAAP product gross margin | 85.3 | % | 71.8 | % | 84.5 | % | 73.5 | % | ||||||||
| Stock-based compensation expenses | — | % | — | % | — | % | 0.1 | % | ||||||||
| Acquisition related-amortization of purchased intangibles | 3.0 | % | 2.6 | % | 3.3 | % | 1.3 | % | ||||||||
| Variable interest entity consolidated costs (2) | 0.1 | % | — | % | — | % | — | % | ||||||||
| Non-GAAP product gross margin(1) | 88.3 | % | 74.5 | % | 87.9 | % | 74.9 | % | ||||||||
| Research and development expenses reconciliation: | ||||||||||||||||
| GAAP research and development expenses | $ | 1,045 | $ | 552 | $ | 2,854 | $ | 2,120 | ||||||||
| Stock-based compensation expenses | (41 | ) | (30 | ) | (152 | ) | (109 | ) | ||||||||
| Restructuring expenses | — | — | — | (4 | ) | |||||||||||
| Acquisition related expenses | (85 | ) | — | (85 | ) | — | ||||||||||
| Acquisition related-contingent consideration remeasurement | (20 | ) | (11 | ) | (32 | ) | (59 | ) | ||||||||
| Non-GAAP research and development expenses | $ | 899 | $ | 511 | $ | 2,585 | $ | 1,948 | ||||||||
| Selling, general and administrative expenses reconciliation: | ||||||||||||||||
| GAAP selling, general and administrative expenses | $ | 876 | $ | 513 | $ | 2,983 | $ | 1,699 | ||||||||
| Stock-based compensation expenses | (52 | ) | (42 | ) | (198 | ) | (136 | ) | ||||||||
| Restructuring expenses | — | — | — | 2 | ||||||||||||
| Acquisition related-amortization of purchased intangibles | (15 | ) | — | (18 | ) | (1 | ) | |||||||||
| Acquisition related-transaction costs | (1 | ) | — | (1 | ) | (7 | ) | |||||||||
| Variable interest entity consolidated costs (2) | (9 | ) | — | (9 | ) | — | ||||||||||
| Non-GAAP selling, general and administrative expenses | $ | 799 | $ | 471 | $ | 2,757 | $ | 1,557 | ||||||||
| Operating margin reconciliation: | ||||||||||||||||
| GAAP operating margin | 59.2 | % | 38.4 | % | 61.3 | % | 40.4 | % | ||||||||
| Stock-based compensation expenses | 1.3 | % | 2.3 | % | 1.4 | % | 2.3 | % | ||||||||
| Restructuring expenses | — | % | — | % | — | % | — | % | ||||||||
| Acquisition related expenses/transaction costs | 1.2 | % | — | % | 0.3 | % | 0.1 | % | ||||||||
| Acquisition related-amortization of purchased intangibles | 3.2 | % | 2.6 | % | 3.4 | % | 1.3 | % | ||||||||
| Acquisition related-contingent consideration remeasurement | 0.3 | % | 0.4 | % | 0.1 | % | 0.5 | % | ||||||||
| Variable interest entity consolidated costs (2) | 0.1 | % | — | % | — | % | — | % | ||||||||
| Non-GAAP operating margin(1) | 65.2 | % | 43.6 | % | 66.6 | % | 44.5 | % | ||||||||
| Other income (expense) reconciliation: | ||||||||||||||||
| GAAP other income (expense), net | $ | 30 | $ | (11 | ) | $ | 3 | $ | (9 | ) | ||||||
| Acquisition related-transaction costs | — | — | (2 | ) | — | |||||||||||
| Non-GAAP other income (expense), net | $ | 30 | $ | (11 | ) | $ | 1 | $ | (9 | ) | ||||||
|
(1) Amounts may not sum due to rounding |
||||||||||||||||
| (2) Consolidation of a contract manufacturer | ||||||||||||||||
|
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued) (unaudited) (in millions, except percentages and per share amounts) |
||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Effective tax rate reconciliation: | ||||||||||||||||
| GAAP effective tax rate | 18.2 | % | 29.3 | % | 18.8 | % | 27.3 | % | ||||||||
| Restructuring expenses | — | % | — | % | — | % | — | % | ||||||||
| Acquisition related-transaction costs | — | % | — | % | — | % | — | % | ||||||||
| Acquisition related-amortization of purchased intangibles | (0.8 | )% | (1.5 | )% | (0.9 | )% | (0.4 | )% | ||||||||
| Acquisition related-contingent consideration remeasurement | (0.1 | )% | (0.3 | )% | — | % | (0.4 | )% | ||||||||
| Non-GAAP effective tax rate(1) | 17.3 | % | 27.5 | % | 17.9 | % | 26.5 | % | ||||||||
| Net income attributable to Gilead reconciliation: | ||||||||||||||||
| GAAP net income attributable to Gilead | $ | 3,487 | $ | 791 | $ | 12,101 | $ | 3,075 | ||||||||
| Stock-based compensation expenses | 79 | 53 | 296 | 185 | ||||||||||||
| Restructuring expenses | — | — | — | 3 | ||||||||||||
| Acquisition related expenses/transaction costs | 71 | — | 70 | 7 | ||||||||||||
| Acquisition related-amortization of purchased intangibles | 226 | 75 | 815 | 122 | ||||||||||||
| Acquisition related-contingent consideration remeasurement | 20 | 11 | 32 | 59 | ||||||||||||
| Non-GAAP net income attributable to Gilead | $ | 3,883 | $ | 930 | $ | 13,314 | $ | 3,451 | ||||||||
| Diluted earnings per share reconciliation: | ||||||||||||||||
|
GAAP diluted earnings per share |
$ | 2.18 | $ | 0.47 | $ | 7.35 | $ | 1.81 | ||||||||
| Stock-based compensation expenses | 0.05 | 0.03 | 0.18 | 0.11 | ||||||||||||
| Restructuring expenses | — | — | — | — | ||||||||||||
| Acquisition related expenses/transaction costs | 0.04 | — | 0.04 | — | ||||||||||||
| Acquisition related-amortization of purchased intangibles | 0.14 | 0.04 | 0.49 | 0.07 | ||||||||||||
| Acquisition related-contingent consideration remeasurement | 0.01 | 0.01 | 0.02 | 0.03 | ||||||||||||
| Non-GAAP diluted earnings per share(1) | $ | 2.43 | $ | 0.55 | $ | 8.09 | $ | 2.04 | ||||||||
| Shares used in per share calculation (diluted) reconciliation: | ||||||||||||||||
| GAAP shares used in per share calculation (diluted) | 1,597 | 1,694 | 1,647 | 1,695 | ||||||||||||
| Share impact of current stock-based compensation rules | (1 | ) | (1 | ) | (1 | ) | (1 | ) | ||||||||
| Non-GAAP shares used in per share calculation (diluted) | 1,596 | 1,693 | 1,646 | 1,694 | ||||||||||||
| Non-GAAP adjustment summary: | ||||||||||||||||
| Cost of goods sold adjustments | $ | 216 | $ | 80 | $ | 824 | $ | 150 | ||||||||
| Research and development expenses adjustments | 146 | 41 | 269 | 172 | ||||||||||||
| Selling, general and administrative expenses adjustments | 77 | 42 | 226 | 142 | ||||||||||||
| Other income (expense) adjustments | — | — | (2 | ) | — | |||||||||||
| Total non-GAAP adjustments before tax | 439 | 163 | 1,317 | 464 | ||||||||||||
| Income tax effect | (38 | ) | (25 | ) | (99 | ) | (88 | ) | ||||||||
| Less: variable interest entity consolidated costs (2) | (5 | ) | — | (5 | ) | — | ||||||||||
| Total non-GAAP adjustments after tax attributable to Gilead | $ | 396 | $ | 138 | $ | 1,213 | $ | 376 | ||||||||
| (1) Amounts may not sum due to rounding | ||||||||||||||||
| (2) Consolidation of a contract manufacturer | ||||||||||||||||
|
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in millions) |
|||||||
| December 31, | December 31, | ||||||
| 2014 | 2013 (1) | ||||||
| Cash, cash equivalents and marketable securities | $ | 11,726 | $ | 2,571 | |||
| Accounts receivable, net | 4,635 | 2,182 | |||||
| Inventories | 1,386 | 1,697 | |||||
| Property, plant and equipment, net | 1,674 | 1,166 | |||||
| Intangible assets, net | 11,073 | 11,900 | |||||
| Goodwill | 1,172 | 1,169 | |||||
| Other assets | 2,998 | 1,894 | |||||
| Total assets | $ | 34,664 | $ | 22,579 | |||
| Current liabilities | $ | 5,618 | $ | 6,407 | |||
| Long-term liabilities | 13,212 | 4,363 | |||||
| Equity component of redeemable convertible notes | 15 | 64 | |||||
| Stockholders’ equity(2) | 15,819 | 11,745 | |||||
| Total liabilities and stockholders’ equity | $ | 34,664 | $ | 22,579 | |||
| (1) Derived from the audited consolidated financial statements as of December 31, 2013. Certain prior period amounts have been reclassified to conform to the current presentation. |
| (2) As of December 31, 2014, there were 1,499 shares of common stock issued and outstanding. |
|
GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited) (in millions) |
|||||||||||||||
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| December 31, | December 31, | ||||||||||||||
| 2014 | 2013 | 2014 | 2013 | ||||||||||||
| Antiviral products: | |||||||||||||||
| Harvoni – U.S. | $ | 2,001 | $ | — | $ | 2,001 | $ | — | |||||||
| Harvoni – Europe | 83 | — | 103 | — | |||||||||||
| Harvoni – Other International | 23 | — | 23 | — | |||||||||||
| 2,107 | — | 2,127 | — | ||||||||||||
| Sovaldi – U.S. | 1,178 | 136 | 8,507 | 136 | |||||||||||
| Sovaldi – Europe | 459 | 3 | 1,546 | 3 | |||||||||||
| Sovaldi – Other International | 95 | — | 230 | — | |||||||||||
| 1,732 | 139 | 10,283 | 139 | ||||||||||||
| Atripla – U.S. | 668 | 615 | 2,357 | 2,356 | |||||||||||
| Atripla – Europe | 194 | 255 | 888 | 1,061 | |||||||||||
| Atripla – Other International | 63 | 63 | 225 | 231 | |||||||||||
| 925 | 933 | 3,470 | 3,648 | ||||||||||||
| Truvada – U.S. | 548 | 416 | 1,787 | 1,570 | |||||||||||
| Truvada – Europe | 287 | 325 | 1,275 | 1,296 | |||||||||||
| Truvada – Other International | 62 | 73 | 278 | 270 | |||||||||||
| 897 | 814 | 3,340 | 3,136 | ||||||||||||
| Stribild – U.S. | 319 | 187 | 1,014 | 510 | |||||||||||
| Stribild – Europe | 52 | 14 | 145 | 24 | |||||||||||
| Stribild – Other International | 14 | 3 | 38 | 5 | |||||||||||
| 385 | 204 | 1,197 | 539 | ||||||||||||
| Complera / Eviplera – U.S. | 196 | 152 | 663 | 503 | |||||||||||
| Complera / Eviplera – Europe | 138 | 96 | 513 | 268 | |||||||||||
| Complera / Eviplera – Other International | 14 | 14 | 52 | 39 | |||||||||||
| 348 | 262 | 1,228 | 810 | ||||||||||||
| Viread – U.S. | 164 | 123 | 484 | 428 | |||||||||||
| Viread – Europe | 77 | 92 | 336 | 354 | |||||||||||
| Viread – Other International | 70 | 52 | 238 | 177 | |||||||||||
| 311 | 267 | 1,058 | 959 | ||||||||||||
| Other Antiviral – U.S. | 12 | 10 | 46 | 57 | |||||||||||
| Other Antiviral – Europe | 7 | 10 | 35 | 45 | |||||||||||
| Other Antiviral – Other International | 2 | 2 | 7 | 9 | |||||||||||
| 21 | 22 | 88 | 111 | ||||||||||||
| Total antiviral products – U.S. | 5,086 | 1,639 | 16,859 | 5,560 | |||||||||||
| Total antiviral products – Europe | 1,297 | 795 | 4,841 | 3,051 | |||||||||||
| Total antiviral products – Other International | 343 | 207 | 1,091 | 731 | |||||||||||
| 6,726 | 2,641 | 22,791 | 9,342 | ||||||||||||
| Other products: | |||||||||||||||
| Letairis | 181 | 139 | 595 | 520 | |||||||||||
| Ranexa | 144 | 130 | 510 | 449 | |||||||||||
| AmBisome | 104 | 94 | 388 | 352 | |||||||||||
| Zydelig | 17 | — | 23 | — | |||||||||||
| Other | 50 | 39 | 167 | 141 | |||||||||||
| 496 | 402 | 1,683 | 1,462 | ||||||||||||
| Total product sales | $ | 7,222 | $ | 3,043 | $ | 24,474 | $ | 10,804 | |||||||
Source:
Gilead Sciences, Inc.
Investors
Robin
Washington, 650-522-5688
Patrick O'Brien, 650-522-1936
Media
Amy
Flood, 650-522-5643